The earnings call reflected a predominantly positive outlook with record revenues, strong earnings growth, and the successful launch of a new product line. However, some challenges remain, such as a decline in international sales and potential operational inefficiencies. Overall, the company shows a strong trajectory for growth.

Company Guidance -

Q3 2025

During the IRADIMED CORPORATION second quarter 2025 financial results conference call, the company provided updated financial guidance along with detailed performance metrics. IRADIMED reported a revenue of $20.4 million for Q2 2025, which marks a 14% increase from the same period in 2024. The gross profit margin remained robust at 78%, with GAAP diluted earnings per share increasing by 18% year-over-year. The company anticipates Q3 2025 revenue to be between $20.5 million and $20.9 million, reflecting a growth of 12% to 14% compared to Q3 2024, and expects full-year 2025 revenues to range from $80 million to $82.5 million, representing a 9% to 13% increase over 2024. IRADIMED also projects GAAP diluted earnings per share for 2025 to be between $1.60 and $1.70. Notably, the company is poised for significant future growth with the FDA clearance of its new 3870 IV pump system, which is expected to drive substantial replacement demand, potentially reaching a $100 million revenue run rate by 2026.

Record-Breaking Quarter

IRADIMED reported its 16th consecutive quarter of record revenues with $20.4 million, a 14% increase over the same period last year.

Strong Earnings Growth

GAAP diluted earnings per share increased by 18% from Q2 of 2024, reflecting strong financial performance.

New Product Launch

The FDA cleared the new 3870 IV pump systems for distribution, anticipated to significantly drive future sales.

Raised Financial Guidance

For the full year 2025, revenue guidance was raised to $80 million to $82.5 million, indicating 9% to 13% growth over 2024.

High Domestic Sales Growth

Domestic sales increased by 18% to $18.2 million, making up 89% of total revenue.

Iradimed (IRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IRMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 31, 2025	2025 (Q3)	0.46 / -	0.43	―	―	―
Aug 01, 2025	2025 (Q2)	0.43 / 0.49	0.42	16.67% (+0.07)	―
May 05, 2025	2025 (Q1)	0.41 / 0.42	0.36	16.67% (+0.06)	―
Feb 13, 2025	2024 (Q4)	0.44 / 0.44	0.39	12.82% (+0.05)	―
Oct 31, 2024	2024 (Q3)	0.41 / 0.43	0.43	0.00% (0.00)
Aug 01, 2024	2024 (Q2)	0.36 / 0.42	0.36	16.67% (+0.06)	―
May 02, 2024	2024 (Q1)	0.34 / 0.36	0.3	20.00% (+0.06)	―
Feb 08, 2024	2023 (Q4)	0.38 / 0.39	0.32	21.88% (+0.07)	―
Nov 03, 2023	2023 (Q3)	0.36 / 0.43	0.29	48.28% (+0.14)	―
Aug 03, 2023	2023 (Q2)	0.31 / 0.36	0.26	38.46% (+0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IRMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 01, 2025	$58.34	$66.17	+13.42%
May 05, 2025	$53.30	$52.14	-2.18%
Feb 13, 2025	$60.11	$55.06	-8.40%
Oct 31, 2024	$52.47	$48.83	-6.94%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Iradimed Corp (IRMD) report earnings?

Iradimed Corp (IRMD) is schdueled to report earning on Oct 31, 2025, Before Open (Confirmed).

What is Iradimed Corp (IRMD) earnings time?

Iradimed Corp (IRMD) earnings time is at Oct 31, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IRMD EPS forecast?

IRMD EPS forecast for the fiscal quarter 2025 (Q3) is 0.46.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing